KM Research Hub
← 返回论文库
待处理 入排:待复核 图源:待检查 入排置信度 0.00

Prognostic impact of diabetes or hypertension in smokers with CRPC receiving enzalutamide or abiraterone.

Takashi Fukagai, Kouji Izumi, Motoki Yamagishi, Takashi Shima, Yuki Kato, Koji Mita, Takehiko Okamura, Shogo Inoue, Shuichi Tatarano, Nobumichi Tanaka, Noriyasu Kawai, Manabu Kamiyama, Ippei Chikazawa, Seiji Hoshi, Kohei Hashimoto, Kazuyoshi Shigehara, Shizuko Takahara, Atsushi Mizokami

Int J Clin Oncol 31(11) 2673-2683

PMID42762423
PMCID-
DOI10.1007/s10147-026-03178-w
发表日期2026-09-19
入排依据:未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。
摘要

摘要

BACKGROUND: Smoking and lifestyle‑related diseases increase the risk of cancer incidence and progression, but their impact on castration‑resistant prostate cancer (CRPC) remains unclear. This study examined whether diabetes mellitus (DM), hypertension (HT), and smoking habit (SH) affect the prognosis of CRPC patients treated with enzalutamide (ENZ) or abiraterone plus prednisolone (ABI). METHODS: Using data from the ENABLE study for PCa, an investigator‑initiated, multicenter, randomized controlled trial, patients were retrospectively categorized into two groups based on SH. Subsequently, the impact of the absence or presence of either DM or HT and treatment arm (ENZ or ABI) on survival endpoints was investigated. RESULTS: A total of 178 patients were randomized and treated, of whom 161 had available SH information and were included in the analysis (84 SH- and 77 SH+). No significant differences in survival endpoints were observed between the SH- and SH+ groups. In the SH+ group, prostate cancer-specific survival (PCSS) was significantly worse in the with‑DM/HT group than in the no‑DM/HT group (p = 0.0215). Multivariate Cox analysis confirmed that the presence of DM or HT was an independent predictor of poor PCSS. Furthermore, a significant difference in PCSS between the no‑DM/HT and with‑DM/HT groups was observed in the ENZ arm (p = 0.0201), but not in the ABI arm. CONCLUSIONS: SH does not appear to influence the efficacy of ENZ or ABI therapy for CRPC; however, among SH+ patients, the presence of DM or HT was associated with poorer survival outcomes, particularly in those treated with ENZ.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。